Gemini Pharmaceuticals
Gemini Pharmaceuticals, a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across various regions. Founded in 2003, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. Gemini Pharmaceuticals is renowned for its innovative approach to drug formulation, focusing on complex generics and niche therapeutic areas. Their commitment to quality and regulatory compliance has earned them a strong market position, with notable achievements in product launches and partnerships. With a diverse portfolio that includes injectables, oral solids, and topical formulations, Gemini Pharmaceuticals continues to meet the evolving needs of healthcare providers and patients alike, solidifying its reputation as a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Gemini Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Metal Fabrication industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gemini Pharmaceuticals's score of 3 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Gemini Pharmaceuticals's reported carbon emissions
Gemini Pharmaceuticals currently does not have available carbon emissions data, as no specific figures have been provided. Consequently, there are no reported emissions for the most recent year or any details regarding Scope 1, 2, or 3 emissions. In the absence of concrete emissions data, it is important to note that the company has not outlined any specific reduction targets or initiatives related to carbon emissions. Additionally, there are no commitments to the Science Based Targets initiative (SBTi) or any climate pledges that would indicate a structured approach to addressing climate change. As the pharmaceutical industry increasingly focuses on sustainability, it is crucial for companies like Gemini Pharmaceuticals to establish clear climate commitments and reduction strategies to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gemini Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
